KRAS G12D
Clinical trials for KRAS G12D explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D trials appear
Sign up with your email to follow new studies for KRAS G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-stage study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. …
Matched conditions: KRAS G12D
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 26, 2026 10:32 UTC
-
Supercharged immune cells take on hard-to-treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment using a patient's own immune cells, modified in a lab to recognize and attack cancer cells with a specific KRAS mutation (G12D). It is for adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not respond…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 10:29 UTC
-
New immunotherapy option for pancreatic cancer patients with no other choices
Disease control AVAILABLEThis program provides early access to an experimental immunotherapy called ELI-002 7P for people with a specific type of pancreatic cancer (KRAS/NRAS-mutated) who have had their tumor removed but are at high risk of the cancer coming back. It is for patients who have no other tre…
Matched conditions: KRAS G12D
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug targets Hard-to-Treat KRAS cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 20, 2026 11:58 UTC
-
New hope for rare blood vessel disorders: targeted drugs enter trial
Disease control Recruiting nowThis study tests two targeted drugs for people with vascular malformations (abnormal blood or lymph vessels). Participants with slow-flow malformations and a specific gene mutation receive alpelisib, while those with fast-flow malformations and another mutation receive mirdametin…
Matched conditions: KRAS G12D
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New t cell therapy targets hard-to-treat KRAS G12D cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new cell therapy called RE002 for people with advanced solid tumors that have a specific genetic mutation (KRAS G12D). The treatment uses the patient's own immune cells, modified to recognize and attack the cancer. The study aims to see if the treat…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 19, 2026 11:48 UTC